A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Atezolizumab|DRUG: Paclitaxel|DRUG: Dose-dense Doxorubicin or dose-dense Epirubicin|DRUG: Cyclophosphamide
Sponsor: Hoffmann-La Roche
Collaborators: Breast International Group|Alliance Foundation Trials (AFT)|Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)|Frontier Science & Technology Research Foundation, Inc.